# Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. is a public company headquartered in Arlington, MA, United States.

## Company overview

- **Legal name:** Eloxx Pharmaceuticals, Inc.
- **Former names in filing history:** Sevion Therapeutics, Inc. (2014-10-03 to 2017-12-22); SENESCO TECHNOLOGIES INC (1999-11-19 to 2014-09-29); NAVA LEISURE USA INC (1997-10-07 to 1999-05-24)
- **Classification:** Public company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Arlington, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001035354

## About

Eloxx Pharmaceuticals develops investigational small-molecule medicines designed to promote ribosomal readthrough of premature stop codons caused by nonsense mutations. Its lead candidate, exaluren, is being studied for rare kidney diseases. ZKN-013 targets rare skin diseases through a collaboration with Almirall. The programs seek to restore production of full-length proteins, but their intended mechanisms are distinct from established patient benefit or regulatory approval. Its reported principal executive office is in Arlington, MA (United States). For fiscal 2025, ended 2025-12-31, its originally reported results included revenue of USD 0; a net loss of USD 5,995,000; cash used in operations of USD 6,327,000. At that year-end, it reported total assets of USD 5,270,000 and cash and cash equivalents of USD 4,785,000.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$6.0M (USD -5,995,000)
- **Total assets:** $5.3M (USD 5,270,000)
- **Cash and equivalents:** $4.8M (USD 4,785,000)
- **Operating cash flow:** -$6.3M (USD -6,327,000)

### FY2022 (period ended 2022-12-31)

- **Net income:** -$36.1M (USD -36,065,000)
- **Total assets:** $21.1M (USD 21,123,000)
- **Cash and equivalents:** $19.2M (USD 19,207,000)
- **Operating cash flow:** -$31.8M (USD -31,845,000)

### FY2021 (period ended 2021-12-31)

- **Net income:** -$66.7M (USD -66,727,000)
- **Total assets:** $45.1M (USD 45,139,000)
- **Cash and equivalents:** $42.3M (USD 42,268,000)
- **Operating cash flow:** -$35.0M (USD -35,001,000)

### FY2020 (period ended 2020-12-31)

- **Net income:** -$34.6M (USD -34,577,000)
- **Total assets:** $26.5M (USD 26,477,000)
- **Cash and equivalents:** $24.7M (USD 24,668,000)
- **Operating cash flow:** -$28.2M (USD -28,166,000)

## Recent SEC filings

- Form S-1 — filed 2026-09-11 — S-1
- Form 8-K — filed 2026-08-11 — period 2026-08-11 — 8-K
- Form 10-Q — filed 2026-08-11 — period 2026-06-30 — 10-Q
- Form 424B4 — filed 2026-06-09 — 424B4
- Form 8-K — filed 2026-06-01 — period 2026-05-27 — 8-K
- Form S-1 — filed 2026-05-07 — S-1
- Form 10-Q — filed 2026-05-05 — period 2026-03-31 — 10-Q
- Form 8-K — filed 2026-05-01 — period 2026-04-28 — 8-K
- Form 10-K — filed 2026-03-17 — period 2025-12-31 — 10-K
- Form 8-K — filed 2025-08-12 — period 2025-08-06 — FORM 8-K
- Form 8-K — filed 2024-10-17 — period 2024-10-16 — FORM 8-K
- Form 8-K — filed 2024-07-16 — period 2024-07-10 — FORM 8-K

---

Updated: 2026-10-15T21:34:01.423Z

Canonical page: https://altss.com/profile/eloxx-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology